Safe use of highly steatotic livers by utilizing a donor/recipient clinical algorithm

Clinical Transplantation

Volumn 27, Issue 5, 2013, Pages 732-741

  Chavin, Kenneth D ^a   Taber, David J ^a   Norcross, Melissa ^a   Pilch, Nicole A ^b   Crego, Heather ^a   Mcgillicuddy, John W ^a   Bratton, Charles F ^a   Lin, Angello ^a   Baliga, Prabhakar K ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Graft survival; Liver transplantation; Organ allocation; Patient survival; Steatosis

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ALGORITHM; ARTICLE; COMPARATIVE STUDY; DONOR SELECTION; FATTY LIVER; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; LENGTH OF STAY; LIVER FUNCTION; LIVER INJURY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; REPERFUSION INJURY; RISK ASSESSMENT; SURGEON;

GRAFT SURVIVAL; LIVER TRANSPLANTATION; ORGAN ALLOCATION; PATIENT SURVIVAL; STEATOSIS;

ADULT; ALGORITHMS; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; REPERFUSION INJURY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84884981585     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12211     Document Type: Article

References (51)

1. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, 2011.
2. Nocito A, El-Badry AM, Clavien PA. When is steatosis too much for transplantation? J Hepatol 2006: 45: 494.
3. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999: 282: 1519.
4. Rao AR, Chui AK, Shi LW, Tsai L, Leon CD, Sheil AG. Is donor obesity related to liver steatosis and liver graft dysfunction in liver transplantation? Transplant Proc 2000: 32: 2103.
5. Rinella ME, Alonso E, Rao S et al. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl 2001: 7: 409.
6. Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 2004: 4: 686.
7. Todo S, Demetris AJ, Makowka L et al. Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989: 47: 903.
8. D'Alessandro AM, Kalayoglu M, Sollinger HW et al. The predictive value of donor liver biopsies on the development of primary nonfunction after orthotopic liver transplantation. Transplant Proc 1991: 23: 1536.
9. Ploeg RJ, D'Alessandro AM, Knechtle SJ et al. Risk factors for primary dysfunction after liver transplantation-a multivariate analysis. Transplantation 1993: 55: 807.
10. Fiorini RN, Kirtz J, Periyasamy B et al. Development of an unbiased method for the estimation of liver steatosis. Clin Transplant 2004: 18: 700.
11. Fiorentino M, Vasuri F, Ravaioli M et al. Predictive value of frozen-section analysis in the histological assessment of steatosis before liver transplantation. Liver Transpl 2009: 15: 1821.
12. Feng S, Goodrich NP, Bragg-Gresham JL et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006: 6: 783.
13. Spitzer AL, Lao OB, Dick AA et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl 2010: 16: 874.
14. Afonso RC, Saad WA, Parra OM, Leitao R, Ferraz-Neto BH. Impact of steatotic grafts on initial function and prognosis after liver transplantation. Transplant Proc 2004: 36: 909.
15. Alwayn IP, Porte RJ. How to make steatotic livers suitable for transplantation. Liver Transpl 2007: 13: 480.
16. Briceno J, Ciria R, Pleguezuelo M et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl 2009: 15: 37.
17. Burra P, Loreno M, Russo FP et al. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl 2009: 15: 619.
18. Deroose JP, Kazemier G, Zondervan P, Ijzermans JN, Metselaar HJ, Alwayn IP. Hepatic steatosis is not always a contraindication for cadaveric liver transplantation. HPB 2011: 13: 417.
19. Doyle MB, Vachharajani N, Wellen JR et al. Short- and long-term outcomes after steatotic liver transplantation. Arch Surg 2010: 145: 653.
20. Gao F, Xu X, Ling Q et al. Efficacy and safety of moderately steatotic donor liver in transplantation. Hepatobiliary Pancreat Dis Int 2009: 8: 29.
21. Gordon FD, Pomfret EA, Pomposelli JJ, Lewis WD, Jenkins RL, Khettry U. Severe steatosis as the initial histologic manifestation of recurrent hepatitis C genotype 3. Hum Pathol 2004: 35: 636.
22. Kwon CH, Joh JW, Lee KW et al. Safety of donors with fatty liver in liver transplantation. Transplant Proc 2006: 38: 2106.
23. Marsman WA, Wiesner RH, Rodriguez L et al. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996: 62: 1246.
24. McCormack L, Clavien PA. Understanding the meaning of fat in the liver. Liver Transpl 2005: 11: 137.
25. McCormack L, Dutkowski P, El-Badry AM, Clavien PA. Liver transplantation using fatty livers: always feasible? J Hepatol 2011: 54: 1055.
26. McCormack L, Petrowsky H, Jochum W, Mullhaupt B, Weber M, Clavien PA. Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg 2007: 246: 940.
27. Imber CJ, St Peter SD, Lopez I, Guiver L, Friend PJ. Current practice regarding the use of fatty livers: a trans-Atlantic survey. Liver Transpl 2002: 8: 545.
28. Halon A, Patrzalek D, Rabczynski J. Hepatic steatosis in liver transplant donors: rare phenomenon or common feature of donor population? Transplant Proc 2006: 38: 193.
29. Verran D, Dilworth P, Tang P, McCaughan G. Use of severely steatotic grafts in liver transplantation. Ann Surg 2008: 248: 142.
30. Urena MA, Moreno Gonzalez E, Romero CJ, Ruiz-Delgado FC, Moreno Sanz C. An approach to the rational use of steatotic donor livers in liver transplantation. Hepatogastroenterology 1999: 46: 1164.
31. Soejima Y, Shimada M, Suehiro T et al. Use of steatotic graft in living-donor liver transplantation. Transplantation 2003: 76: 344.
32. Perez-Daga JA, Santoyo J, Suarez MA et al. Influence of degree of hepatic steatosis on graft function and postoperative complications of liver transplantation. Transplant Proc 2006: 38: 2468.
33. Peralta C, Rosello-Catafau J. The future of fatty livers. J Hepatol 2004: 41: 149.
34. Fung J. Liver transplantation for fatty liver disease. J Digest Dis 2011: 12: 36.
35. Li J, Liu B, Yan LN et al. Reversal of graft steatosis after liver transplantation: prospective study. Transplant Proc 2009: 41: 3560.
36. Sharkey FE, Lytvak I, Prihoda TJ, Speeg KV, Washburn WK, Halff GA. High-grade microsteatosis and delay in hepatic function after orthotopic liver transplantation. Hum Pathol 2011: 42: 1337.
37. Cieslak B, Lewandowski Z, Urban M, Ziarkiewicz-Wroblewska B, Krawczyk M. Microvesicular liver graft steatosis as a risk factor of initial poor function in relation to suboptimal donor parameters. Transplant Proc 2009: 41: 2985.
38. Muscari F, Guinard JP, Foppa B et al. Biological changes after liver transplantation according to the presence or not of graft steatosis. Transplant Proc 2008: 40: 3562.
39. Yilmaz N, Shiffman ML. Impact of the donor liver with steatosis in patients with hepatitis C virus: not so FAst. Liver Transpl 2009: 15: 4.
40. Testino G, Borro P. Hepatitis C recurrence: influence of serum cholesterol levels and liver steatosis on antiviral therapy. Hepatology 2011: 53: 1409.
41. Subramanian V, Seetharam AB, Vachharajani N et al. Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation. Transplantation 2011: 92: 1259.
42. Yamashiki N, Sugawara Y, Tamura S et al. Noninvasive estimation of hepatic steatosis in living liver donors: usefulness of visceral fat area measurement. Transplantation 2009: 88: 575.
43. Silva MA. Putting objectivity into assessment of steatosis. Transplantation 2009: 88: 620.
44. Kim SH, Lee JM, Han JK et al. Hepatic macrosteatosis: predicting appropriateness of liver donation by using MR imaging-correlation with histopathologic findings. Radiology 2006: 240: 116.
45. Rey JW, Wirges U, Dienes HP, Fries JW. Hepatic steatosis in organ donors: disparity between surgery and histology? Transplant Proc 2009: 41: 2557.
46. Angelico M. Donor liver steatosis and graft selection for liver transplantation: a short review. Eur Rev Med Pharmacol Sci 2005: 9: 295.
47. Fishbein TM, Fiel MI, Emre S et al. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 1997: 64: 248.
48. Angele MK, Rentsch M, Hartl WH et al. Effect of graft steatosis on liver function and organ survival after liver transplantation. Am J Surg 2008: 195: 214.
49. Cho JY, Suh KS, Kwon CH, Yi NJ, Lee KU. Mild hepatic steatosis is not a major risk factor for hepatectomy and regenerative power is not impaired. Surgery 2006: 139: 508.
50. Noujaim HM, de Ville de Goyet J, Montero EF, et al. Expanding postmortem donor pool using steatotic liver grafts: a new look. Transplantation 2009: 87: 919.
51. Baccarani U, Isola M, Adani GL, et al. Steatosis of the hepatic graft as a risk factor for post-transplant biliary complications. Clin Transplant 2010: 24: 631.